Company intelligence / Profile preview
Resverlogix Corp.
Calgary, Alberta, Canadaresverlogix.com ↗
- Ownership
- Public · RVX
- Employees
- ~19
- Development stage
- Phase 3
01
Overview
Completed Phase 3 clinical trial (BETonMACE) for apabetalone in high-risk cardiovascular disease patients with type 2 diabetes mellitus and low HDL. Apabetalone received Breakthrough Therapy Designation from the FDA for a major cardiovascular indication. Also conducting Phase 2 trials for COVID-19 treatment.
- Therapeutic areas
- EndocrinologyCardiovascularInfectious DiseasesNephrology
- Modalities
- Small molecules (specifically BET inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
EVERSANA (for commercialization)Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (financing)
04
Financials
- Market cap
- $17.1M
- Total revenue
- $0
- Enterprise value
- $94.7M
Beyond the preview
Go deeper on Resverlogix Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Resverlogix Corp..